Gynaecological cancer

Mel-Mont Medical announces the validation of its patented self-sampling technology, Mía by XytoTest®, for molecular screening using HPV-DNA and 7-Type mRNA E6/E7.

Retrieved on: 
Wednesday, August 4, 2021
Cancer, Infectious causes of cancer, Papillomavirus, Gynaecological cancer, Sexually transmitted diseases and infections, Vaccines, Human papillomavirus infection, Cervical cancer, HPV vaccine, HspE7

KLOKKARSTUA, Norway, Aug. 4, 2021 /PRNewswire/ -- Mel-Mont Medical, a boutique medical device and technology company dedicated to improving women's health through the use of its DNA and mRNA patented self-sampling screening kit, Mia by XytoTest®, receives clinical validation as being equally effective to clinician-collected sampling.

Key Points: 
  • "Current estimates indicate that every year 569,847 women are diagnosed with cervical cancer, and 311,365 die from the disease.
  • Cervical cancer ranks as the third most frequent cancer among women in the world," according to Globocan information center on HPV and cancer.
  • The uniqueness of Ma by XytoTest empowers sexually active women to further their self-care opportunities and pre-screen for HPV-caused cancers.
  • PreTect AS, a fully ISO 13485:2016, CE/IVD certified, and FDA registered mRNA manufacturing facility based in Klokkarstua, Norway, is a wholly-owned subsidiary of Mel-Mont Medical, Inc.

Zentalis Pharmaceuticals Announces First Patient Dosed in Potentially Registrational Phase 2 Study of ZN-c3 in Patients with Uterine Serous Carcinoma

Retrieved on: 
Monday, August 2, 2021
Gynaecological cancer, Endometrial cancer, Uterine serous carcinoma, Cancer, Endometrium, Medicine, Uterine clear-cell carcinoma, Health sciences

Despite current treatment options, USC a highly aggressive form of endometrial cancer has an extremely poor prognosis, with survival rates ranging between 30-50%.

Key Points: 
  • Despite current treatment options, USC a highly aggressive form of endometrial cancer has an extremely poor prognosis, with survival rates ranging between 30-50%.
  • The Phase 2 trial (ZN-c3-004) is an open-label, multicenter study evaluating the clinical activity, safety, pharmacokinetics, and related biomarkers of ZN-c3 in patients with recurrent or persistent USC.
  • Uterine serous carcinoma (USC) is an aggressive variant of endometrial cancer that accounts for less than 10% of all endometrial cancers, yet 80% of endometrial cancerrelated deaths.
  • Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers.

Cervical Intraepithelial Neoplasia (CIN) - Global Clinical Trials Review H2, 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 29, 2021
Health, Clinical trials, Health, Infectious causes of cancer, Clinical medicine, Gynaecological cancer, Papillomavirus, Vaccines, Intraepithelial neoplasia, Lesion, Cervical intraepithelial neoplasia, Cin, Clinical trial, HspE7

The "Cervical Intraepithelial Neoplasia (CIN) - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cervical Intraepithelial Neoplasia (CIN) - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • "Cervical Intraepithelial Neoplasia (CIN) - Global Clinical Trials Review, H2, 2021" provides an overview of the Cervical Intraepithelial Neoplasia (CIN) Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Cervical Intraepithelial Neoplasia (CIN).
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
    The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
    The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
    Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
    Facilitates clinical trial assessment of the indication on a global, regional and country level
    Clinical Trials by G7 Countries: Proportion of Cervical Intraepithelial Neoplasia (CIN) to Women's Health Clinical Trials
    Clinical Trials by E7 Countries: Proportion of Cervical Intraepithelial Neoplasia (CIN) to Women's Health Clinical Trials

Mersana Therapeutics Announces Initiation of the UPGRADE Phase 1 Platinum Combination Cohort for UpRi in Platinum-Sensitive Ovarian Cancer

Retrieved on: 
Wednesday, July 28, 2021
Gynaecology, Oncology, Gynaecological cancer, Ovarian cancer

The initial arm of this umbrella study is evaluating carboplatin in combination with UpRi followed by continuation of UpRi monotherapy in patients with platinum-sensitive ovarian cancer.

Key Points: 
  • The initial arm of this umbrella study is evaluating carboplatin in combination with UpRi followed by continuation of UpRi monotherapy in patients with platinum-sensitive ovarian cancer.
  • The initiation of UPGRADE is another important milestone for Mersana as we work to build UpRi into a foundational medicine in the treatment of ovarian cancer, said Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics.
  • The initiation of the UPGRADE umbrella study is a critical first step in evaluating the potential of UpRi in earlier lines of therapy.
  • We are excited to initiate UPGRADE and are beginning with a platinum combination because platinum remains the mainstay therapy in earlier-line platinum-sensitive ovarian cancer.

Lawyers for Ovarian Cancer Victims Call on Regulators to Stop 'Contemptible' Johnson & Johnson Bankruptcy Plan

Retrieved on: 
Monday, July 19, 2021
Cancer, Minerals, Crystallography, Oncology, Gynaecological cancer, Excipients, Phyllosilicates, Talc, Ovarian cancer

Dozens of studies published in peer-reviewed journals during the past 25 years have shown a statistically significant association between talc use and ovarian cancer.

Key Points: 
  • Dozens of studies published in peer-reviewed journals during the past 25 years have shown a statistically significant association between talc use and ovarian cancer.
  • Documents produced at trial show that the company was aware of the possible dangers as far back as the 1960s.
  • A bankruptcy filing could significantly reduce the compensation available to remaining claimants and would prevent them from having their day in court.
  • Headquartered in Montgomery, Ala., Beasley Allen is comprised of more than 70 attorneys and 200 support staff.

AIDOT Accelerates Its Export Drive for AI Remote Readout System to Developing Markets

Retrieved on: 
Tuesday, July 13, 2021
Software, Mobile, Wireless, Professional services, Internet, Oncology, Consumer, Technology, Medical devices, Small business, University, Education, Women, Health, Gynaecological cancer, Infectious causes of cancer, Cervical cancer, Acetic acid, Cervical, Clinical medicine, Health, Medicine

AIDOT Inc. , a medical ICT company, announced that it has strengthened exporting Cerviray AI, a cervical cancer remote readout system, to enhance women's health in developing countries where medical infrastructure is not sufficient.

Key Points: 
  • AIDOT Inc. , a medical ICT company, announced that it has strengthened exporting Cerviray AI, a cervical cancer remote readout system, to enhance women's health in developing countries where medical infrastructure is not sufficient.
  • View the full release here: https://www.businesswire.com/news/home/20210713005524/en/
    AIDOT Inc., a Korean medical ICT company, has strengthened exporting Cerviray AI, a cervical cancer remote readout system, to enhance women's health in developing countries where medical infrastructure is not sufficient.
  • The Cerviray AI of AIDOT has been developed with an aim of improving women's health in global markets where medical infrastructure is lacking.
  • By employing the Visual Inspection with Acetic acid technique, the Cerviray AI is the first such device that has adopted AI and contactless remote solution.

Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Advanced Solid Tumors and Aggressive Lymphomas

Retrieved on: 
Tuesday, July 13, 2021
Endometrial cancer, Gynaecological cancer, Women's health

The study has initially opened at City of Hope and MD Anderson Cancer Center with more sites to join later on.

Key Points: 
  • The study has initially opened at City of Hope and MD Anderson Cancer Center with more sites to join later on.
  • In addition, a patient with MCL1 amplified, advanced endometrial cancer experienced deep PR and 100% shrinkage of her target tumor lesions on single agent fadraciclib treatment.
  • We are excited to begin mid-stage development of fadraciclib with the objective of registration-enabling outcomes and offering a new treatment option for patients with advanced solid tumors or lymphomas.
  • The Phase 1/2 registration-directed trial (CYC065-101) uses a streamlined design and will first determine the recommended Phase 2 dose (RP2D) for single-agent, oral fadraciclib.

US Ovarian Cancer Market and Competitive Landscape Report 2021: Phase 3, Phase 2, and Phase 1 by Pharmacological Class and Companies Developing the Products - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 13, 2021
Health, Oncology, Cancer, Gynaecology, Gynaecological cancer, Oncology, Ovarian cancer, Health, Medical specialties

The "US Ovarian Cancer Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Ovarian Cancer Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • US Ovarian Cancer Market and Competitive Landscape Highlights - 2021 provides comprehensive insights into Ovarian Cancer pipeline products, Ovarian Cancer epidemiology, Ovarian Cancer market valuations and forecast, Ovarian Cancer drugs sales and competitive landscape in the US.
  • Ovarian Cancer pipeline: Find out the products in clinical trials for the treatment of Ovarian Cancer by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Ovarian Cancer drugs: Identify key products marketed and prescribed for Ovarian Cancer in the US, including trade name, molecule name, and company
    Ovarian Cancer market valuations: Find out the market size for Ovarian Cancer drugs in 2019 in the US.
  • Find out how the market advanced from 2017 and forecast to 2026
    Ovarian Cancer drugs market share: Find out the market shares for key Ovarian Cancer drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Ovarian Cancer products

Human Papillomavirus (HPV) Vaccines Disease Analysis Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 8, 2021
Infectious diseases, Pharmaceutical, Health, Medical devices, Cancer, Clinical medicine, Medicine, Papillomavirus, Infectious causes of cancer, Vaccines, Cancer vaccines, Gynaecological cancer, Human papillomavirus infection, Papillomaviridae, Cervical cancer, Papilloma

The "Disease Analysis: Human Papillomavirus (HPV) Vaccines" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Disease Analysis: Human Papillomavirus (HPV) Vaccines" report has been added to ResearchAndMarkets.com's offering.
  • Worldwide vaccination programs for human papillomavirus (HPV) have evolved substantially over the last decade.
  • HPV infection is the major cause of cervical cancers, with almost all cases (99%) being caused by HPV infection.
  • Both vaccines are based on the recombinant expression of major capsid antigen L1 from different HPV serotypes, which self-assemble into virus-like particles (VLPs).

North America HPV Testing and Pap Test Market Potential, Industry Analysis and Forecast Report 2021-2027 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 6, 2021
Women, Other Health, Consumer, Health, Oncology, Cancer, Infectious causes of cancer, Gynaecological cancer, Papillomavirus, Carcinogens, Human papillomavirus infection, Pap test, Cervical cancer, HPV vaccine, Cervical screening

The "North America HPV Testing and Pap Test Market By Type, By Application, By Product, By End Use, By Country, Growth Potential, Industry Analysis Report and Forecast, 2021 - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North America HPV Testing and Pap Test Market By Type, By Application, By Product, By End Use, By Country, Growth Potential, Industry Analysis Report and Forecast, 2021 - 2027" report has been added to ResearchAndMarkets.com's offering.
  • Therefore, the growing number of cervical cancer cases may surge the demand for HPV testing and PAP tests, boosting the market growth.
  • Thus, the growing cases of cervical cancer across the North American region are expected to boost the demand for HPV testing and Pap test market over the forthcoming years.
  • The US market dominated the North America HPV Testing Market by Country 2020, thereby, achieving a market value of $844.5 million by 2027.